Loading clinical trials...
Loading clinical trials...
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Chu Dijon Bourgogne
Dijon, France
Start Date
November 1, 2019
Primary Completion Date
September 1, 2021
Completion Date
September 1, 2021
Last Updated
June 23, 2020
44
ESTIMATED participants
injection of BEP 800
DRUG
Control
OTHER
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions